Fatal interstitial lung disease associated with oral erlotinib therapy for lung cancer

BACKGROUND: Erlotinib is a Human Epidermal Growth Factor Receptor Type 1/tyrosine kinase (EGFR) inhibitor which is used for non-small-cell lung cancer treatment. Despite that erlotinib is considered to have a favorable safety profile, adverse events such as interstitial lung disease (ILD) were repor...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Makris, Demosthenes, Scherpereel, Arnaud, Copin, Marie Christine, Colin, Guillaume, Brun, Luc, Lafitte, Jean Jacques, Marquette, Charles Hugo
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2007
Matèries:
Case Report
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC1963454/
https://ncbi.nlm.nih.gov/pubmed/17683587
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-7-150
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars